By Connor Hart
Shares of Curis jumped after the company released what it assessed as positive data from a study of its in-development treatment for leukemia.
The stock was up 33%, to $4.07, in midday trading Thursday. Shares ended 2024 down 73%.
The Lexington, Mass., biotech company said its treatment, emavusertib, resulted in 10 objective responses out of 19 response-evaluable patients. Six patients achieved complete remission; two achieved complete remission with either incomplete or partial hematological recovery, meaning that blood cell counts haven't fully returned to normal; and two achieved a morphologic leukemia-free state, which indicates the disappearance of leukemia cells and bone marrow recovery.
Emavusertib previously received orphan drug designation, a regulatory status granted to drugs or biologics intended to treat rare diseases or conditions, from the Food and Drug Administration for the treatment of acute myeloid leukemia and myelodysplastic syndrome, and from the European Commission for the treatment of primary central nervous system lymphoma.
"We continue to be pleased with the monotherapy data in R/R AML patients with a FLT3 mutation and believe these data further support the exciting potential of emavusertib's novel mechanism to address a significant unmet need in patients with AML," Chief Executive James Dentzer said.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
January 02, 2025 12:45 ET (17:45 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。